Summary
Abbott Laboratories (ABT) is a premier pharmaceutical company and has been a great long-term investment over the years.
-Five year average annual revenue growth rate: 9.5%
-Five year average annual income growth rate: 6.5%
-Five year average annual dividend growth rate: 9%
-Current dividend yield: 3.74%
-Balance sheet strength: Fair
I find Abbott to be a solid value right now. The current P/E ratio is a bit high, and forward P/E is significantly lower and more of a value. Although reliant on the continued success of Humira, Abbott is otherwise highly diversified. In addition, the dividend yield is significant, and dividend growth is strong.
Overview
Founded in 1888, Abbott Laboratories (ABT) produces a large variety of pharmaceutical products and nutritional products. They produce everything from Vicodin to coronary stints to Ensure, and have 90,000 employees in 130 countries.
The company had $35.2 billion in sales for 2010. A bit over 42% of this came from the United States, and the remainder came from other countries. The Pharmaceutical Segment was responsible for 57% of total sales, Nutritionals accounted for 16% of total sales, Diagnostics accounted for 11%, Vascular accounted for 9% of total sales, and 7% came from other sources.
Revenue, Earnings, Cash Flow, and Metrics
Abbott has strong growth and consistent performance.
Revenue Growth
Year | Revenue |
---|---|
2010 | $35.2 billion |
2009 | $30.8 billion |
2008 | $29.5 billion |
2007 | $25.9 billion |
2006 | $22.5 billion |
2005 | $22.3 billion |
Revenue growth has averaged 9.5% annually over this five year period.
Income Growth
Year | Income |
---|---|
2010 | $4.63 billion |
2009 | $5.75 billion |
2008 | $4.73 billion |
2007 | $3.61 billion |
2006 | $1.72 billion |
2005 | $3.37 billion |
Abbott’s income has increased at an average annual rate of 6.5% over the past 5 years. This calculation was significantly affected by the reduced net income for 2010 compared to 2009.
In 2010, prepaid expenses and accounts payable contributed significantly to the fact that Abbott this year had particularly high cash flow and rather low net income. This is a matter of timing that should smooth out next year.
Cash Flow Growth
Year | Operational Cash Flow | Free Cash Flow |
---|---|---|
2010 | $8.74 billion | $7.72 billion |
2009 | $7.26 billion | $6.19 billion |
2008 | $7.00 billion | $5.71 billion |
2007 | $5.18 billion | $3.53 billion |
2006 | $5.26 billion | $3.92 billion |
2005 | $5.05 billion | $3.84 billion |
Annualized, Abbott has had average operational cash flow growth of 11.5%, and free cash flow growth of 15%, over the past five years.
Metrics
Price to Earnings: 17.3
Price to FCF: 10.2
Price to Book: 3.5
Net Profit Margin: 13.2%
Return on Equity: 20.6%
Dividend Growth
Abbot currently has a dividend yield of over 3.70%, which is historically and recently high for the stock. Abbott has increased dividends for the past 38 consecutive years.
Dividend Growth
Year | Dividend | Yield |
---|---|---|
2010 | $1.72 | 3.50% |
2009 | $1.56 | 3.40% |
2008 | $1.41 | 2.60% |
2007 | $1.29 | 2.50% |
2006 | $1.18 | 2.60% |
2005 | $1.10 | 2.50% |
Dividend growth has averaged over 9% annually for the past 5 years. For 2011, Abbott increased the quarterly dividend from $0.44 to $0.48, which represents a 9% increase.
The dividend payout ratio was under 60% in 2010, so their dividend is very-well covered by earnings and is positioned to continue growing. 2010 was a low year for EPS compared to 2009, so normally the payout ratio is lower.
Balance Sheet
LT Debt to Equity is about 0.56, which is decent. However, a significant part of Abbott’s growth comes from acquisitions, so the accumulated goodwill consists of 70% of shareholder equity, which is higher than I’d like to see. The interest coverage ratio is over 10, which is strong.
Overall, this means Abbott has a moderately strong balance sheet. They are neither too conservative nor overly-leveraged. Some other health care investments that I’ve considered on this site, Becton Dickinson (BDX) and Johnson and Johnson (JNJ), both have stronger balance sheets, but Abbott’s financial position is still reasonable. It is comparable to the financial position of Medtronic (MDT).
Investment Thesis
Abbott is consistent, has great historical performance, appears to have considerable growth potential going forward, and pays a good dividend that increases every year.
Abbott has continued its expansion into emerging markets in 2010, with acquisitions of Solvay Pharmaceuticals and Piramal Healthcare Solutions, and a collaboration with Zydus Cadilla. After the Piramal acquisition, Abbott claims the leading position for pharmaceuticals in India, and the company expects the Indian pharmaceutical market to double in the next five years. A bit under one-quarter of Abbott’s sales are from emerging markets, and in five years, Abbott expects this to shift up to one-third. Over the past ten years, Abbott has more than quadrupled its total international sales.
With the exception of Humira, which makes up a significant percentage of Abbott’s total sales, Abbott is quite diversified. The company has leading positions in the American pharmaceutical market, especially in the areas of autoimmune diseases, HIV, and lipid management. The company has hundreds of generic medicines across the world, over 100 brands of medical devices, and 50 worldwide nutrition brands. The company has many Phase II and Phase III compounds in its pipeline, and expects to have 20 new molecular entities in Phase II or Phase III development by the end of this year. For medical devices, the company has plans to launch several diagnostics products over the few years, and expects 20 new products and advancements from their vision care pipeline over the next five years.
Overall, I am in favor of investments in the health care industry currently. The life expectancy around the world varies significantly by geographic region. North America, Western Europe, Australia, and the highly developed East Asian countries lead the world with expectancies ranging from the mid-70s to the 80s. Behind them are South America, the Middle East, Eastern Europe, and some portions of Asia including China with life expectancies in the 70s. Many portions of Africa and Asia are behind, with life expectancies being in the 40s, 50s, and 60s. As the world hopefully improves economically, health care is going to continue playing a large role. Abbott invested $3.7 billion in research in development in 2010, which is a more than $1 billion increase compared to other recent years.
Risks
Overall, I believe Abbott is a relatively conservative stock investment, but is not without risks. Like other health care companies, they face patent risks and large lawsuits. Abbott must continue to develop new products to replace products that having expiring patents, either organically, through partnerships, or through acquisitions. Increasing regulation is a challenge that Abbott will continue to face.
Humira, a drug for six different autoimmune diseases, accounted for $6.5 billion in sales for 2010, representing nearly 20% of the total sales. This is up from $5.5 billion in 2009 and $4.5 billion in 2008. As stated in the 2010 annual report, Abbott expects Humira sales growth in the low teens for 2011. Humira is an immensely profitable drug, and represents a significant portion of Abbott sales and profitability. Any threats to Humira would affect Abbott very materially.
Conclusion
In conclusion, I find Abbott to be a reasonable value at the current price. The diversified operations in pharmaceuticals, medical devices, and nutrition are impressive, the balance sheet is fair, and I particularly like the focus on expansion into emerging markets. The company’s focus on acquisitions helps the company to reduce risk and strengthen their otherwise lackluster pipeline, but compared to organic growth, this reduces profitability potential and leads to the accumulation of goodwill on the balance sheet.
I consider Abbott stock to be a reasonable buy in the low-mid $50’s. Today’s price is a bit over $51.
Full Disclosure: I own shares of ABT, JNJ, BDX, and MDT.
You can see my full list of individual holdings here.
Information used in this report came from official Abbot material, including the 2010 annual report, as well as other sources external to Abbott.
Further Reading:
Johnson and Johnson (JNJ) Dividend Stock Analysis
National Presto (NPK) Dividend Stock Analysis
Becton Dickinson (BDX) Dividend Stock Analysis
AZZ Incorporated (AZZ) Dividend Stock Analysis
AGL Resources (AGL) Dividend Stock Analysis